盘后时段
|
||||
|
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.14/-1.04
|
|
企业价值
474.57M
|
| 资产负债 |
|
每股账面净值
3.67
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
80.00M
|
|
每股收益
0.05
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟:2025/11/17 17:21 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. |

9.46 

9.65